Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma

American Journal of Neuroradiology

Volumn 31, Issue 1, 2010, Pages 60-66

  Barajas Jr , R F ^a   Rubenstein, J L ^b   Chang, J S ^a   Hwang, J ^c   Cha, Soonmee ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CELL DENSITY; CELL HETEROGENEITY; CLINICAL ARTICLE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG MEGADOSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MEASUREMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGRESSION FREE SURVIVAL;

BRAIN NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 75749155906     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A1750     Document Type: Article

References (34)

1. Statistical Report: Primary Brain Tumors in the United States, 1998 -2002. Hinsdale, Ilinois: Central Brain Tumor Registry of the United States; 2005
2. Surawicz TS, McCarthy BJ, Kupelian V, et al. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro Oncol 1999;1:14-25
3. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 2002;95:1504-10
4. Hochberg F, Baehring J, Hochberg E. Primary CNS lymphoma. Nat Clin Pract Neurol 2007;3:24-35
5. Abrey LE, Batchelor TT, Ferreri AJ, et al, for the International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034-43. Epub 2005 Jun 13
6. Glass J, Gruber ML, Cher L, et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994;81:188-95
7. Gavrilovic IT, Hormigo A, Yahalom J, et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006;28:4570-74
8. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998;16:859-63
9. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007;25:1350 -56. Epub 2007 Feb 20
10. Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma. J Clin Oncol 2008;26:2512-18
11. Le Bihan D, Turner R, Douek P, et al. Diffusion MR imaging: clinical applications. AJR Am J Roentgenol 1992;159:591-99
12. Rowley HA, Grant PE, Roberts TP. Diffusion MR imaging: theory and applications. Neuroimaging Clin N Am 1999;9:343-61
13. Le Bihan D, Breton E, Lallemand D, et al.MRimaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986;161:401-07
14. Guo AC, Cummings TJ, Dash RC, et al. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002;224:177-83
15. Rubenstein J, Shen A, Batchelor T, et al. Differential gene expression in central nervous system lymphoma. Blood 2009;113:266-67
16. Rubenstein, J, Fridlyand, J, Shen, A., et al. Gene expression and angiotropism in primary CNS lymphoma. Blood 2006;107:3716-23
17. Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998;16:864-71
18. Burger PC, Shibata T, Kleihues P. The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol 1986;10:611-17
19. Matsumoto Y, Horiike S, Fujimoto Y, et al. Effectiveness and limitation of gamma knife radiosurgery for relapsed central nervous system lymphoma: a retrospective analysis in one institution. Int J Hematol 2007;85:333-37
20. Ryken TC, Meeks SL, Pennington EC, et al. Initial clinical experience with frameless stereotactic radiosurgery: analysis of accuracy and feasibility. Int J Radiat Oncol Biol Phys 2001;51:1152-58
21. Roy S, Josephson SA, Fridlyand J, et al. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol 2008;26:96-105
22. Ducreux D,WuRH, Mikulis DJ, et al. Diffusion-weighted imaging and single-voxel MR spectroscopy in a case of malignant cerebral lymphoma. Neuroradiology 2003;45:865-68
23. Stadnik TW, Chaskis C, Michotte A, et al. Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histologic findings. AJNR Am J Neuroradiol 2001;22:969-76
24. Kitis O, Altay H, Calli C, et al. Minimum apparent diffusion coefficients in the evaluation of brain tumors. Euro J Radiol 2005;55:393-400
25. Reiche W, Hagen T, Schuchardt V, et al. Diffusion-weighted MR imaging improves diagnosis of CNS lymphomas: a report of four cases with common and uncommon imaging features. Clin Neurol Neurosurg 2007;109:92-101
26. Toh CH, Castillo M, Wong AM, et al. Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR Am J Neuroradiol 2008;29:471-75
27. O'Neill BP, Kelly PJ, Earle JD, et al. Computer-assisted stereotaxic biopsy for the diagnosis of primary central nervous system lymphoma. Neurology 1987;37:1160-64
28. Murray K, Kun L, Cox J. Primary malignant lymphoma of the central nervous system, result of treatment of 11 cases and review of the literature. J Neursosurg 1986;65:600-07
29. O'Neill BP, Illig JJ. Primary central nervous system lymphoma. Mayo Clin Proc 1989;64:1005-20
30. McAllister LD, Doolittle ND, Guastadisegni PE, et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000;46:51-61
31. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 2005;102:5524-29
32. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92:2029-36
33. Mardor Y, Pfeffer R, Spiegelmann R, et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 2003;21:1094-100
34. Hamstra DA, Chenevert TL, Moffat BA, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 2005;102:16759-64